Palbociclib belongs to several generations of targeted drugs

Palbociclib (Palbociclib) is a targeted or biological therapy that is taken with hormonal (endocrine) therapy when used to treat breast cancer. Palbociclibis the generic name for this drug; its brand name isIbrance. Pabociclib is a second-generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds for its favorable physical and pharmaceutical properties.

Targeted drugs refer to drugs that can act on specific molecular targets of tumor cells and inhibit the growth and spread of cancer cells. Palbociclib These drugs block the action of kinases, proteins that help cells grow and divide. By doing this, they stop the cancer from growing and spreading. Although palbociclib is a second-generation targeted drug, new targeted drugs are still being researched and developed to improve the effect of anti-tumor treatment. Palbociclib is not currently used for early-stage (primary) breast cancer.

PalbociclibThe original drug has been launched in China and has been included in medical insurance. Currently, reimbursement is only available to patients who meet the indications. The common specifications100mg*21 pills may cost more than 6,000 yuan per box, while the original drug sold overseas is more expensive. The price of 125mg*21 pills per box may be around 10,000 yuan (the price may fluctuate due to exchange rates). Palbociclib generics are also sold overseas. The ingredients of the drug are basically the same as those sold domestically and abroad, but the price is cheap. For example, the price of a box of 125mg*21 tablets produced by a Bangladesh pharmaceutical factory may be several hundred yuan (the price may fluctuate due to the exchange rate).